Routine weekly buyback disclosure with no change to program parameters. Monitor for any acceleration or deceleration in repurchase pace relative to the remaining ~DKK 4.75 billion authorization through February 2027.
Price Chart
Executive Summary
Novo Nordisk filed a routine 6-K disclosing weekly share repurchase transactions under its ongoing buyback program. The company repurchased 1,225,000 B shares for approximately DKK 307.4 million during the week ending October 2, 2026, at an average price of ~DKK 250.96 per share. This is a routine administrative update with no material new information.
Key Facts
- Total buyback program of up to DKK 15 billion over 12 months beginning February 4, 2026
- Sub-program initiated May 6, 2026 authorizes up to DKK 11.2 billion in repurchases through February 1, 2027
- Week ending October 2, 2026: 1,225,000 B shares repurchased for ~DKK 307.4 million
- Cumulative repurchases under sub-program: 21,845,000 B shares for DKK 6.45 billion
- Total repurchases since February 4, 2026: 36,604,179 B shares at avg DKK 279.95 for DKK 10.25 billion
- Treasury shares now total 50,644,876 B shares, representing 1.1% of total share capital
Financial Impact
Routine buyback disclosure, no material financial impact. Cumulative spend of DKK 10.25 billion against a DKK 15 billion authorization.
Risk Factors
- No new risks identified, this is a standard periodic update on an existing buyback program
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-006440 |
| Document: 0001171843-26-006440-index-headers.html | 0001171843-26-006440 |
| Document: 0001171843-26-006440-index.html | 0001171843-26-006440 |
| Document: 0001171843-26-006440.txt | 0001171843-26-006440 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 3d ago | 6-K | $39.13 | awaiting T+20 | awaiting T+20 | $39.08 (−0.13%) |
Oct 26, 2026 3d ago | Court Ruling | $38.67 | awaiting T+20 | awaiting T+20 | $39.08 (+1.06%) |
Oct 19, 2026 10d ago | 6-K | $38.42 | awaiting T+20 | awaiting T+20 | $39.08 (+1.72%) |
Oct 13, 2026 16d ago | 6-K | $38.06 | awaiting T+20 | awaiting T+20 | $39.08 (+2.68%) |
Oct 6, 2026 23d ago | 6-K | $37.53 | awaiting T+20 | awaiting T+20 | $39.08 (+4.13%) |
Sep 28, 2026 4w ago | 6-K | $38.71 $38.95 | ▲ +0.61% | ▲ +0.64% | $39.08 (+0.96%) |
Sep 23, 2026 5w ago | Court Ruling | $38.62 $39.43 | ▲ +2.10% | ▲ +2.52% | $39.08 (+1.19%) |
Sep 21, 2026 5w ago | 6-K | $39.80 $38.42 | ▼ −3.47% | ▼ −2.56% | $39.08 (−1.81%) |
Sep 17, 2026 6w ago | 6-K | $43.19 $39.22 | ▼ −9.19% | ▼ −10.40% | $39.08 (−9.52%) |
Sep 15, 2026 6w ago | 6-K | $42.53 $38.06 | ▼ −10.51% | ▼ −13.23% | $39.08 (−8.11%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers